These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30950636)

  • 1. Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation.
    Maher TM; Lancaster LH; Jouneau S; Morrison L; Lederer DJ; Molina-Molina M; Bendstrup E; Kirchgaessler KU; Gilberg F; Axmann J; Petzinger U; Noble PW
    Ann Am Thorac Soc; 2019 Jul; 16(7):927-930. PubMed ID: 30950636
    [No Abstract]   [Full Text] [Related]  

  • 2. A real-world study of the dosing and tolerability of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis.
    Dhooria S; Agarwal R; Sehgal IS; Prasad KT; Muth V; Garg M; Bal A; Aggarwal AN; Behera D
    Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):148-157. PubMed ID: 33093778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis.
    Nathan SD; Costabel U; Glaspole I; Glassberg MK; Lancaster LH; Lederer DJ; Pereira CA; Trzaskoma B; Morgenthien EA; Limb SL; Wells AU
    Chest; 2019 Apr; 155(4):712-719. PubMed ID: 30472023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis.
    Loeh B; Drakopanagiotakis F; Bandelli GP; von der Beck D; Tello S; Cordani E; Rizza E; Barrocu L; Markart P; Seeger W; Guenther A; Albera C
    Am J Respir Crit Care Med; 2015 Jan; 191(1):110-3. PubMed ID: 25551350
    [No Abstract]   [Full Text] [Related]  

  • 5. Composite Physiologic Index, Percent Forced Vital Capacity and Percent Diffusing Capacity for Carbon Monoxide Could Be Predictors of Pirfenidone Tolerability in Patients with Idiopathic Pulmonary Fibrosis.
    Konishi S; Arita M; Ito I; Tachibana H; Takaiwa T; Fukuda Y; Watanabe N; Tsubouchi K; Masuda G; Tanaka M; Kourogi Y; Kunimasa K; Nishiyama A; Iwasaku M; Ito A; Tokioka F; Yoshioka H; Hashimoto T; Ishida T
    Intern Med; 2015; 54(22):2835-41. PubMed ID: 26567995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study.
    Sakamoto S; Muramatsu Y; Satoh K; Ishida F; Kikuchi N; Sano G; Sugino K; Isobe K; Takai Y; Homma S
    Respirology; 2015 Apr; 20(3):445-52. PubMed ID: 25639750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.
    Ley B; Swigris J; Day BM; Stauffer JL; Raimundo K; Chou W; Collard HR
    Am J Respir Crit Care Med; 2017 Sep; 196(6):756-761. PubMed ID: 28471697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis.
    Arai T; Inoue Y; Sasaki Y; Tachibana K; Nakao K; Sugimoto C; Okuma T; Akira M; Kitaichi M; Hayashi S
    Respir Investig; 2014 Mar; 52(2):136-43. PubMed ID: 24636270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
    Nathan SD; Costabel U; Albera C; Behr J; Wuyts WA; Kirchgaessler KU; Stauffer JL; Morgenthien E; Chou W; Limb SL; Noble PW
    Respir Med; 2019 Jul; 153():44-51. PubMed ID: 31153107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis.
    Chaudhuri N; Duck A; Frank R; Holme J; Leonard C
    Respir Med; 2014 Jan; 108(1):224-6. PubMed ID: 24269005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
    Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
    Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Patient with Idiopathic Pleuroparenchymal Fibroelastosis Showing a Sustained Pulmonary Function due to Treatment with Pirfenidone.
    Sato S; Hanibuchi M; Takahashi M; Fukuda Y; Morizumi S; Toyoda Y; Goto H; Nishioka Y
    Intern Med; 2016; 55(5):497-501. PubMed ID: 26935370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pirfenidone in idiopathic pulmonary fibrosis.
    Taniguchi H; Ebina M; Kondoh Y; Ogura T; Azuma A; Suga M; Taguchi Y; Takahashi H; Nakata K; Sato A; Takeuchi M; Raghu G; Kudoh S; Nukiwa T;
    Eur Respir J; 2010 Apr; 35(4):821-9. PubMed ID: 19996196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis.
    Glassberg MK; Wijsenbeek MS; Gilberg F; Petzinger U; Kirchgaessler KU; Albera C
    Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31164431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Experience of the Long-term Use of Pirfenidone for Idiopathic Pulmonary Fibrosis.
    Bando M; Yamauchi H; Ogura T; Taniguchi H; Watanabe K; Azuma A; Homma S; Sugiyama Y;
    Intern Med; 2016; 55(5):443-8. PubMed ID: 26935361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
    Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis.
    Ogura T; Taniguchi H; Azuma A; Inoue Y; Kondoh Y; Hasegawa Y; Bando M; Abe S; Mochizuki Y; Chida K; Klüglich M; Fujimoto T; Okazaki K; Tadayasu Y; Sakamoto W; Sugiyama Y
    Eur Respir J; 2015 May; 45(5):1382-92. PubMed ID: 25504994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.
    Karimi-Shah BA; Chowdhury BA
    N Engl J Med; 2015 Mar; 372(13):1189-91. PubMed ID: 25806913
    [No Abstract]   [Full Text] [Related]  

  • 19. Pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis: A retrospective study.
    Furuya K; Sakamoto S; Shimizu H; Sekiya M; Kinoshita A; Isshiki T; Sugino K; Matsumoto K; Homma S
    Respir Med; 2017 May; 126():93-99. PubMed ID: 28427556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan.
    Taguchi Y; Ebina M; Hashimoto S; Ogura T; Azuma A; Taniguchi H; Kondoh Y; Suga M; Takahashi H; Nakata K; Sugiyama Y; Kudoh S; Nukiwa T;
    Respir Investig; 2015 Nov; 53(6):279-87. PubMed ID: 26521105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.